Xue Shengbai, Jiang Weihua, Ma Jingyu, Xu Haiyan, Wang Yanling, Lu Wenxin, Shentu Daiyuan, Cui Jiujie, Li Maolan, Wang Liwei
Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Department of Oncology, Punan Hospital in Pudong New District, Shanghai 200125, China.
Chin Med J (Engl). 2025 Aug 20;138(16):1904-1926. doi: 10.1097/CM9.0000000000003705. Epub 2025 Jul 21.
Cholangiocarcinoma (CCA) is a fatal malignancy with steadily increasing incidence and poor prognosis. Since most CCA cases are diagnosed at an advanced stage, systemic therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, play a crucial role in the management of unresectable CCA. The recent advances in targeted therapies and immunotherapies brought more options in the clinical management of unresectable CCA. This review depicts the advances of targeted therapies and immunotherapies for unresectable CCA, summarizes crucial clinical trials, and describes the efficacy and safety of different drugs, which may help further develop precision and individualization in the clinical treatment of unresectable CCA.
胆管癌（CCA）是一种发病率不断上升且预后较差的致命恶性肿瘤。由于大多数CCA病例在晚期才被诊断出来，全身治疗，包括化疗、放疗、靶向治疗和免疫治疗，在不可切除CCA的管理中起着关键作用。靶向治疗和免疫治疗的最新进展为不可切除CCA的临床管理带来了更多选择。本综述描述了不可切除CCA的靶向治疗和免疫治疗进展，总结了关键临床试验，并描述了不同药物的疗效和安全性，这可能有助于进一步推动不可切除CCA临床治疗的精准化和个体化。
Chin Med J (Engl). 2025-8-20
Cochrane Database Syst Rev. 2018-2-6
J Cancer Res Clin Oncol. 2023-8
Crit Rev Oncol Hematol. 2025-9
Cochrane Database Syst Rev. 2015-12-1
Curr Treat Options Oncol. 2024-1
Zotero 插件